Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
09 April 2024 - 10:00PM
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a
clinical stage biopharmaceutical company focused on developing
multimodal biological immunotherapies to help patients fight
cancer, today announced the presentation of a poster during the
American Association for Cancer Research (AACR) Annual Meeting,
taking place April 5 through 10 in San Diego, which focused on a
first-in-class multimodal immunotherapy candidate for induction of
tertiary lymphoid structures (TLS), being developed as a novel
therapeutic strategy for solid tumors from Candel’s enLIGHTEN™
Discovery Platform.
TLSs are ectopic lymphocyte aggregation
structures found in the tumor microenvironment and their induction
could potentially improve anti-tumor immunity. The presentation
describes the development of an investigational TLS-inducing
multimodal therapeutic using the enLIGHTEN™ Discovery Platform. The
enLIGHTEN™ Advanced Analytics suite was applied to immune
checkpoint inhibitor-treated patient datasets, and the predicted
payload components included factors regulating the development of
TLS. Delivery of two unique in silico predicted payload
combinations, using an enLIGHTEN™ programmable vector, resulted in
TLS induction, monotherapy anti-tumoral activity, and enhanced
responses in combination with anti-PD-1 antibody therapy in mouse
models of solid tumors.
“The recent observation that the presence of TLS
in tumors is an important prognostic factor associated with an
improved response to immunotherapy has fueled drug development
efforts in this area. However, TLS assembly is complicated and
requires a series of events, including antigen presentation,
stromal cell activation, and immune cell activation and
aggregation, which are difficult to obtain with a single
therapeutic,” said Francesca Barone, MD, PhD, Chief Scientific
Officer at Candel. “The enLIGHTEN™ Discovery Platform enables the
generation of multimodal agents through the integration of
artificial intelligence-driven payload combinations into
programmable vectors. This makes it possible to create a single
asset that may induce TLS formation and enhance anti-tumor
immunity.”
“The delivery of the second immunotherapy
candidate based on the enLIGHTEN™ Discovery Platform, on an
accelerated timeline, further validates the ability of this
innovative platform to create new therapeutic candidates at a fast
pace,” added Paul Peter Tak, MD, PhD, FMedSci, President and Chief
Executive Officer of Candel. “Our platform is flexible and
scalable, which makes it suitable for strategic partnerships, for
example to create synergy with CAR-T cell therapy or other
immunotherapies, potentially resulting in improved survival
rates.”
Further detail from Candel’s AACR full poster
presentation is available on the Candel website at:
www.candeltx.com/media.
About the enLIGHTEN™ Discovery
PlatformThe enLIGHTEN™ Discovery Platform is a systematic,
iterative herpes simplex virus (HSV)-based discovery platform
leveraging human biology and advanced analytics to create new
multimodal biological immunotherapies for solid tumors. The
enLIGHTEN™ Discovery Platform has been designed to deconvolute the
characteristics of the tumor microenvironment related to clinical
outcomes. These characteristics are rapidly translated into
optimized multi-gene payloads of tumor modulators that can be
delivered to the tumor microenvironment for specific indications,
disease stages, and rationally designed therapeutic combinations.
In 2022, the Company announced a discovery partnership with the
University of Pennsylvania Center for Cellular Immunotherapies to
create new viral immunotherapies that could enhance the efficacy of
chimeric antigen receptor T cell (CAR-T) therapy in solid tumors.
During the Society for Immunotherapy of Cancer (SITC) 2023 Annual
Meeting and the 2023 International Oncolytic Virus Conference,
Candel presented encouraging data on the first candidate from this
platform, Alpha 201-macro-1, which was designed to interfere with
the CD47/SIRP1α pathway, in mouse models of breast cancer and lung
cancer.
About Candel Therapeutics
Candel is a clinical stage biopharmaceutical
company focused on developing off-the-shelf multimodal biological
immunotherapies that elicit an individualized, systemic anti-tumor
immune response to help patients fight cancer. Candel has
established two clinical stage multimodal biological immunotherapy
platforms based on novel, genetically modified adenovirus and
herpes simplex virus (HSV) gene constructs, respectively. CAN-2409
is the lead product candidate from the adenovirus platform and is
currently in ongoing clinical trials in non-small cell lung cancer
(NSCLC) (phase 2), borderline resectable PDAC (phase 2), and
localized, non-metastatic prostate cancer (phase 2 and phase 3).
CAN-3110 is the lead product candidate from the HSV platform and is
currently in an ongoing investigator-sponsored phase 1 clinical
trial in recurrent high-grade glioma (rHGG). Finally, Candel’s
enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based
discovery platform leveraging human biology and advanced analytics
to create new viral immunotherapies for solid tumors.
For more information about Candel, visit:
www.candeltx.com.
Forward-Looking Statements
This press release includes certain disclosures
that contain “forward-looking statements,” within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, express or implied statements
regarding the timing and advancement of development programs,
including the timing and availability of additional data, and
expectations regarding the therapeutic benefit of the Company’s
programs, and the ability of the enLIGHTEN™ Discovery Platform to
create new multimodal biological immunotherapies for solid tumors
and result in further diversification of the Company’s portfolio as
well as strategic partnerships. The words “may,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, those risks and
uncertainties related to the timing and advancement of development
programs; the Company’s ability to continue as a going concern;
expectations regarding the therapeutics benefit of the Company’s
programs; that final data from the Company’s pre-clinical studies
and completed clinical trials may differ materially from reported
interim data from ongoing studies and trials; the Company’s ability
to efficiently discover and develop product candidates; the
Company’s ability to obtain and maintain regulatory approval of
product candidates; the Company’s ability to maintain its
intellectual property; the implementation of the Company’s business
model, including strategic plans for the Company’s business and
product candidates; and other risks identified in the Company’s
filings with the U.S. Securities and Exchange Commission (SEC)
including the Company’s most recent Annual Report on Form 10-K
filed with the SEC and subsequent filings with the SEC. The Company
cautions you not to place undue reliance on any forward-looking
statements, which speak only as of the date they are made. The
Company disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events,
conditions, or circumstances on which any such statements may be
based, or that may affect the likelihood that actual results will
differ from those set forth in the forward-looking statements. Any
forward-looking statements contained in this press release
represent the Company’s views only as of the date hereof and should
not be relied upon as of the date hereof and should not be relied
upon as representing its views as of any subsequent date.
Investor ContactTheodore
JenkinsVP Investor Relations and Business DevelopmentCandel
Therapeutics, Inc.Tjenkins@candeltx.com
Media ContactAljanae
ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From Apr 2024 to May 2024
Candel Therapeutics (NASDAQ:CADL)
Historical Stock Chart
From May 2023 to May 2024